This assay is to provide Hbl-2-based In Vitro Anti-Tumor Efficacy Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.
Target Cell Name
Hbl-2
Target Cell Organism
Human
Target Cell Background
The HBL-2 cell line is derived from an AIDS-SNCCL (AIDS-associated small non-cleaved cell lymphoma) patient. After immunophenotypic and molecular genetic analysis, the HBL-2 was established from the original tumor clones. The HBL-2 cell line presents surface immunoglobulin and B-cell restricted markers as well as a phenotype consistent with SNCCL; the cell line also displays clonal immunoglobulin gene rearrangement. The HBL-2 cell line is considered useful as a biological model to study AIDS-associated non-Hodgkin lymphomagenesis (AIDS-NHL) and the impacts of biological, immunological, and viral factors involved.
Related Diseases
Mantle Cell Lymphoma; MCL
Research Area
Oncology
Assay Name
In Vitro Anti-Tumor Efficacy Assay
Assay Description
Tumor-derived cell lines have been the mainstay for anti-cancer drug discovery, and the assessment of in vitro efficacy is a common method to evaluate the anti-cancer efficacy with various kinds of therapeutic candidates.